Cambridge Healthtech Institute's Third Annual
Drug Repositioning Summit: Finding New Routes to Success
October 6-7, 2008 Boston, MA
trouble viewing? try this version
Keynote Presentation:
“Repurposing of Enbrel® for Alzheimer’s Disease”
"Many of the novel uses of etanercept which Dr. Tobinick invented, beginning nearly a decade ago, such as for sciatica, Alzheimer’s, and myasthenia gravis, have subsequently been supported by peer-reviewed, published studies performed by independent researchers from academic centers across the globe[18-26].
"As an example, a recently completed, double-blind, placebo-controlled study conducted by independent researchers at Johns Hopkins/Walter Reed Army Medical Center has confirmed the efficacy of etanercept for sciatica, using a patented, perispinal method of administration of etanercept which Dr. Tobinick invented[27]. "
More Information at:
Institute for Neurological Research®, a private medical group, inc.
Read complete transcript with references here
Scientific references for this presentation follow:
1. Tobinick, E., Perispinal etanercept for treatment of Alzheimer's disease. Curr Alzheimer Res, 2007. 4(5): p. 550-2.
2. Tobinick, E., H. Gross, A. Weinberger, and H. Cohen, TNF Modulation
for Treatment of Alzheimer's Disease: A 6-month Pilot Study. Medscape
General Medicine: Neurology, 2006. 8(2): p. 25f.
3. Tobinick, E.,
Perispinal Etanercept Produces Rapid Improvement in Primary Progressive
Aphasia: Identification of a Novel, Rapidly Reversible TNF-Mediated
Pathophysiologic Mechanism. Medscape Journal of Medicine, 2008. 10(6):
p. 135.
4. Tobinick, E.L. and H. Gross, Rapid improvement in
verbal fluency and aphasia following perispinal etanercept in
Alzheimer's disease. BMC Neurol, 2008. 8(1): p. 27.
5. Tobinick,
E.L. and H. Gross, Rapid cognitive improvement in Alzheimer's disease
following perispinal etanercept administration. J Neuroinflammation,
2008. 5: p. 2.
6. Tweedie, D., K. Sambamurti, and N.H. Greig,
TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative
Disorders: New Drug Candidates and Targets. Curr Alzheimer Res, 2007.
4(4): p. 375-8.
7. Tarkowski, E., N. Andreasen, A. Tarkowski, and
K. Blennow, Intrathecal inflammation precedes development of
Alzheimer's disease. J Neurol Neurosurg Psychiatry, 2003. 74(9): p.
1200-5.
8. Laws, S.M., R. Perneczky, S. Wagenpfeil, U. Muller, H.
Forstl, R.N. Martins, A. Kurz, and M. Riemenschneider, TNF
polymorphisms in Alzheimer disease and functional implications on CSF
beta-amyloid levels. Hum Mutat, 2005. 26(1): p. 29-35.
9. Tan,
Z.S., A.S. Beiser, R.S. Vasan, R. Roubenoff, C.A. Dinarello, T.B.
Harris, E.J. Benjamin, R. Au, D.P. Kiel, P.A. Wolf, and S. Seshadri,
Inflammatory markers and the risk of Alzheimer disease: the Framingham
Study. Neurology, 2007. 68(22): p. 1902-8.
10. Ramos, E.M., M.T.
Lin, E.B. Larson, I. Maezawa, L.H. Tseng, K.L. Edwards, G.D.
Schellenberg, J.A. Hansen, W.A. Kukull, and L.W. Jin, Tumor necrosis
factor alpha and interleukin 10 promoter region polymorphisms and risk
of late-onset Alzheimer disease. Arch Neurol, 2006. 63(8): p. 1165-9.
11. Perry, R.T., J.S. Collins, H. Wiener, R. Acton, and R.C. Go, The role
of TNF and its receptors in Alzheimer's disease. Neurobiol Aging, 2001.
22(6): p. 873-83.
12. Tobinick, E., Tumor necrosis factor antagonists for the treatment of neurological disorders. US patent 6,015,557.
13. Tobinick, E., TNF inhibitors for the treatment of neurological disorders. US patent 6,177,077.
14. Tobinick, E., TNF inhibitors for the treatment of neurological, retinal, and muscular disorders. US patent 6,379,666.
15. Tobinick, E., TNF modulators for treating neurological disorders associated with viral infection. US patent 6,419,934.
16. Tobinick, E., TNF inhibitors for the treatment of retinal disorders. US patent 6,428,787.
17. Tobinick, E., Cytokine antagonists for the treatment of localized
disorders. US patent 6,419,944. Also U.S. patents 6,537,549; 6,982,089;
7,214,658; and additional issued and pending U.S. and foreign patents,
including Australian patent 758,523.
18. Griffin, W.S., Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation, 2008. 5: p. 3.
19. Rowin, J., M.N. Meriggioli, E. Tuzun, S. Leurgans, and P.
Christadoss, Etanercept treatment in corticosteroid-dependent
myasthenia gravis. Neurology, 2004. 63(12): p. 2390-2.
20. Anderson, G.M., M.T. Nakada, and M. DeWitte, Tumor necrosis
factor-alpha in the pathogenesis and treatment of cancer. Curr Opin
Pharmacol, 2004. 4(4): p. 314-20.
21. Csiszar, A., N. Labinskyy,
K. Smith, A. Rivera, Z. Orosz, and Z. Ungvari, Vasculoprotective
effects of anti-tumor necrosis factor-alpha treatment in aging. Am J
Pathol, 2007. 170(1): p. 388-98.
22. Medeiros, R., R.D. Prediger,
G.F. Passos, P. Pandolfo, F.S. Duarte, J.L. Franco, A.L. Dafre, G. Di
Giunta, C.P. Figueiredo, R.N. Takahashi, M.M. Campos, and J.B. Calixto,
Connecting TNF-{alpha} Signaling Pathways to iNOS Expression in a Mouse
Model of Alzheimer's Disease: Relevance for the Behavioral and Synaptic
Deficits Induced by Amyloid {beta} Protein. J Neurosci, 2007. 27(20):
p. 5394-5404.
23. Schafers, M. and C. Sommer, Anticytokine
therapy in neuropathic pain management. Expert Rev Neurother, 2007.
7(11): p. 1613-27.
24. Sommer, C. and M. Schafers, Mechanisms of
neuropathic pain: the role of cytokines. Drug Discovery Today: Disease
Mechanisms, 2004. 1(4): p. 441-448.
25. Wacnik, P.W., L.J.
Eikmeier, D.A. Simone, G.L. Wilcox, and A.J. Beitz, Nociceptive
characteristics of tumor necrosis factor-alpha in naive and
tumor-bearing mice. Neuroscience, 2005. 132(2): p. 479-91.
26. Zanella, J.M., E.N. Burright, K. Hildebrand, C. Hobot, M. Cox, L.
Christoferson, and W.F. McKay, Effect of etanercept, a tumor necrosis
factor-alpha inhibitor, on neuropathic pain in the rat chronic
constriction injury model. Spine, 2008. 33(3): p. 227-34.
27. Cohen, S., Efficacy of epidural etanercept in the treatment of sciatica
NCT00364572, results reported at
http://www.clinicaltrials.gov/ct2/show/NCT00733096. 2008, Johns Hopkins
University/Walter Reed Army Medical Center.
28. Tobinick, E. and
S. Davoodifar, Efficacy of etanercept delivered by perispinal
administration for chronic back and/or neck disc-related pain: a study
of clinical observations in 143 patients. Curr Med Res Opin, 2004.
20(7): p. 1075-85.
29. Tobinick, E., The cerebrospinal venous
system: anatomy, physiology, and clinical implications. MedGenMed,
2006. 8(1): p. 53.
30. Tobinick, E.L., Targeted etanercept for
treatment-refractory pain due to bone metastasis: two case reports.
Clin Ther, 2003. 25(8): p. 2279-88.
31. Tobinick, E.L. and S.
Britschgi-Davoodifar, Perispinal TNF-alpha inhibition for discogenic
pain. Swiss Med Wkly, 2003. 133(11-12): p. 170-7.
32. Uceyler, N.
and C. Sommer, Cytokine regulation in animal models of neuropathic pain
and in human diseases. Neurosci Lett, 2008. 437(3): p. 194-8.
33. Van Eldik, L.J., W.L. Thompson, H.R. Ranaivo, H.A. Behanna, and D.M.
Watterson, Proinflammatory Cytokine Upregulation as a Therapeutic
Target for Neurodegenerative Diseases: Function-Based and Target-Based
Discovery Approaches. International Review of Neurobiology, 2007. 82:
p. 278-297.
34. 2007 Progress Report on Brain Research: The Immune System and Alzheimer's. 2007: Dana Alliance for Brain Research.
35. Research Highlights: Perispinal administration of anti-TNF agent
results in rapid cognitive improvement in AD. Nature Clinical Practice
Neurology, 2008. 4(4): p. 181.
36. Auffray, C., Faculty of 1000
Biology: evaluations for Tobinick EL & Gross H J Neuroinflammation
2008 Jan 9 5 (1):2
http://wwwf1000biology.com/article/id/1097874/evaluation. F1000
Biology, 2008.
37. Brimelow, A., BBC News: Hope over US Alzheimer's therapy, at http://news.bbc.co.uk/2/hi/health/7341368.stm. 2008.
38. Elkan, D., Awakenings, in New Scientist. 2008. 199: 2668 p. 32-35.
39. Porciani, F., L’iniezione «miracolosa» che cura l’Alzheimer, in Corriere della Sera. September 6, 2008: Milan.
40. Halassa, M.M., T. Fellin, and P.G. Haydon, The tripartite synapse:
roles for gliotransmission in health and disease. Trends Mol Med, 2007.
13(2): p. 54-63.
41. Hu, N., R. Anwyl, and M. Rowan, Differential
vulnerability of LTP at apical and basal dendrites in the CA1 area to
the inhibitory effects of soluble A-beta in vivo, in Society for
Neuroscience Annual Meeting 2008. abstract 433.8: Washington, D.C.
42. Rowan, M.J., I. Klyubin, Q. Wang, N.W. Hu, and R. Anwyl, Synaptic
memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced
dysfunction. Biochem Soc Trans, 2007. 35(Pt 5): p. 1219-23.
43. Wang, Q., J. Wu, M.J. Rowan, and R. Anwyl, Beta-amyloid inhibition of
long-term potentiation is mediated via tumor necrosis factor. Eur J
Neurosci, 2005. 22(11): p. 2827-32.
44. Stellwagen, D. and R.C. Malenka, Synaptic scaling mediated by glial TNF-alpha. Nature, 2006. 440(7087): p. 1054-9.
45. Bains, J.S. and S.H. Oliet, Glia: they make your memories stick! Trends Neurosci, 2007. 30(8): p. 417-24.
Comments